Table 3.
Study outcomes by apixaban dose.
| Apixaban (reduced dose)* vs. Warfarin | Apixaban (standard dose)* vs. Warfarin | |||||
|---|---|---|---|---|---|---|
| aHR | 95% CI | p-value | aHR | 95% CI | p-value | |
| Stroke/SE | ||||||
| Overall | 0.77 | (0.57, 1.05) | 0.0955 | 0.71 | (0.50, 1.01) | 0.0575 |
| Baseline eGFR group | ||||||
| ≧60 | 0.86 | (0.57, 1.27) | 0.3304 | 0.82 | (0.54, 1.20) | 0.3175 |
| 30–59.9 | 0.68 | (0.42, 1.09) | 0.2522 | 0.48 | (0.20, 1.00) | 0.0605 |
| <30 | 0.66 | (0.23, 1.65) | 0.7231 | - | - | - |
| Major bleeding | ||||||
| Overall | 0.84 | (0.63, 1.12) | 0.2286 | 0.66 | (0.45, 0.96) | 0.0287 |
| Baseline eGFR group | ||||||
| ≧60 | 1.03 | (0.67, 1.57) | 0.5912 | 0.70 | (0.43, 1.11) | 0.0856 |
| 30–59.9 | 0.72 | (0.47, 1.07) | 0.1758 | 0.69 | (0.36, 1.21) | 0.2677 |
| <30 | 0.81 | (0.41, 1.53) | 0.3807 | - | - | - |
*
Apixaban standard dose: 10 mg/day, reduced dose: 2.5–5 mg/day; -: aHR was not available because no event was observed in the advanced CKD subgroup (eGFR <30 ml/min/1.73 m2). aHR: adjusted hazard ratio; 95% CI, 95% confidence interval; eGFR: estimated glomerular filtration rate (ml/min/1.73 m2).